FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								,												
Name and Address of Reporting Person* Llewelyn Linda						2. Issuer Name and Ticker or Trading Symbol Health Catalyst, Inc. [HCAT]								Check	all appli	cable)	ng Person(s) to Iss 10% O Other (s		wner	
	nst) (First) (Middle) O HEALTH CATALYST, INC. 65 MILLROCK DRIVE, #400					3. Date of Earliest Transaction (Month/Day/Year) 02/01/2021								X	below) below) Chief People Officer			-,,		
(Street) SALT LA	AKE U	KE UT 84121				4. If Amendment, Date of Original Filed (Month/Day/Year)								. Indivine)	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																	
		Tab	le I - I	Non-Deriv	/ative	Sec	uritie	es A	cquire	ed, D	isposed o	of, or B	enefici	ally	Owne	t				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y			.	Execution Da		ate,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			Benefic		ties Fo cially (D I Following (I)		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) or Diag		Transac	action(s) 3 and 4)			(
Common Stock 02/01/202				021	21			M		496	A	\$10.	0.8 2		4,104		D			
Common Stock 02/01/202)21	21			S ⁽¹⁾		1,717	D	D \$49.1495		22,387			D				
		Т	able								sposed of , converti				wned					
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amount or Number of Shares	er						
Stock Option (Right to Buy)	\$10.8	02/01/2021			M			496	(3)	09/27/2028	Common Stock	496		\$0.00	37,503	3	D		

Explanation of Responses:

- 1. The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on November 21, 2019, in accordance with Rule 10b5-1. The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on November 21, 2019, in accordance with Rule 10b5-1. The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on November 21, 2019, in accordance with Rule 10b5-1. The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on November 21, 2019, in accordance with Rule 10b5-1. The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on November 21, 2019, in accordance with Rule 10b5-1. The sale reported by the Reporting Person on November 21, 2019, in accordance with Rule 10b5-1. The sale reported by the Reporting Person on November 21, 2019, in accordance with Rule 10b5-1. The sale reported by the Reporting Person on November 21, 2019, in accordance with Rule 10b5-1. The sale reported by the R
- 2. Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from \$48.88 to \$49.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote
- 3. 25% of the 59,351 shares underlying the options vested in an annual installment on September 25, 2019 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on September 25, 2022.

Remarks:

/s/ Daniel Orenstein, as Attorney-in-Fact

02/03/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.